Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Current Assets (2016 - 2025)

Ocular Therapeutix has reported Current Assets over the past 13 years, most recently at $782.1 million for Q4 2025.

  • Quarterly results put Current Assets at $782.1 million for Q4 2025, up 77.36% from a year ago — trailing twelve months through Dec 2025 was $782.1 million (up 77.36% YoY), and the annual figure for FY2025 was $782.1 million, up 77.36%.
  • Current Assets for Q4 2025 was $782.1 million at Ocular Therapeutix, up from $387.0 million in the prior quarter.
  • Over the last five years, Current Assets for OCUL hit a ceiling of $782.1 million in Q4 2025 and a floor of $100.7 million in Q2 2023.
  • Median Current Assets over the past 5 years was $222.3 million (2021), compared with a mean of $297.7 million.
  • Biggest five-year swings in Current Assets: crashed 38.64% in 2023 and later soared 395.06% in 2024.
  • Ocular Therapeutix's Current Assets stood at $191.3 million in 2021, then plummeted by 32.24% to $129.6 million in 2022, then soared by 79.16% to $232.2 million in 2023, then skyrocketed by 89.89% to $441.0 million in 2024, then soared by 77.36% to $782.1 million in 2025.
  • The last three reported values for Current Assets were $782.1 million (Q4 2025), $387.0 million (Q3 2025), and $433.4 million (Q2 2025) per Business Quant data.